| |
Thursday, February 27, 2025 I 12 PM ET See top clinical investigators, medical & trial experts share their game-changing insights to optimize dose escalation, patient recruitment and safety oversight. Register now. +(002)+140w+(1).png)
|
|
Today’s Big NewsFeb 18, 2025 |
|
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome these challenges using AI cloud infrastructure and advanced machine learning tools. |
|
| By James Waldron Fierce Biotech recounts the top 10 clinical trial failures of 2024 that sent ripples across the industry. |
|
|
|
By Gabrielle Masson The National Institutes of Health has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies. |
By Darren Incorvaia Renee Wegrzyn, Ph.D., the inaugural head of the Advanced Research Projects Agency for Health (ARPA-H), has been let go, a Department of Health and Human Services spokesperson confirmed in an email to Fierce Biotech. |
Sponsored by Grifols Nearly one million people in the U.S. and more than six million people worldwide have Parkinson's disease (PD), a debilitating neurological condition characterized by progressive motor and non-motor symptoms that significantly affects patients and their loved ones. |
By Nick Paul Taylor Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet syndrome. |
By James Waldron Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. |
By James Waldron Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are coming in—and it’s led the biotech to abandon its lead asset. |
By Nick Paul Taylor Solid Biosciences has surged back into the Duchenne muscular dystrophy gene therapy race. The biotech reported expectation-busting phase 1 data on its next-generation candidate, sending its stock spiraling upward. |
By James Waldron Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development. |
By Gabrielle Masson Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned. |
By Zoey Becker The company's Penmenvy combines components of its established MenB and MenACWY vaccines Bexsero and Menveo, respectively. |
By Angus Liu The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor type. |
By Amy Maxmen, KFF Health News Without a complete analysis, it’s unclear whether this tidal wave of sickness foreshadows a spike in hospitalizations and deaths that hospitals, pharmacies and schools must prepare for. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we celebrate Valentine's Day with a discussion about heart-related updates and the stories we've loved covering so far this year. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
